Literature DB >> 9706046

A comparison of the bioconversion rates and the Caco-2 cell permeation characteristics of coumarin-based cyclic prodrugs and methylester-based linear prodrugs of RGD peptidomimetics.

G P Camenisch1, W Wang, B Wang, R T Borchardt.   

Abstract

PURPOSE: To compare the bioconversion rates in various biological media and the Caco-2 cell permeation characteristics of coumarin based cyclic prodrugs (3a, 3b) and methylester-based linear prodrugs (1b, 2b) of two RGD peptidomimetics (1a, 2a).
METHODS: Bioconversion rates of the prodrugs to the RGD peptidomimetics were determined in Hank balances salt solution (HBSS), pH 7,4, at 37 degrees C and in various biological media (human blood plasma, rat liver homogenate, Caco-2 cell homogenate) known to have esterase activity. Transport rates of the prodrugs and the RGD peptidomimetics were determined using Caco-2 cell monolayers, an in vitro cell culture model of the intestinal mucosa. RESULTS. In HBSS, pH 7,4, the coumarin-based cyclic prodrugs 3a and 3b degraded slowly and quantitatively to the RGD peptidomimetics 1a and 2a, respectively (3a, t1/2 = 630+2-14 min; 3b, t1/2 = 301 +/-12 min). The methylester-based linear prodrugs 1b and 2b were more stable to chemical hydrolysis (1b and 2b, t1/2 > 2000 min). Both the coumarin-based cyclic prodrugs and the methylester-based linear prodrugs degraded more rapidly in biological media containing esterase activity (e.g., 90% human blood plasma: 1b, t1/2 < 5 min; 2b, t1/2 < 5 min; 3a, t1/2 < 91+/-1 min; 3b, 1/2 < 57+/-2 min). When the apical (AP)-to-basolateral (BL) permeation characteristics were determined using Caco-2 cell monolayers, it was found that the methylester prodrugs 1b and 2b underwent esterase bioconversion (>80%) to the RGD peptidomimetics 1a and 2a, respectively, In contrast, the cyclic prodrugs 3a and 3b permeated the cell monolayers intact. Considering the appearance of both the prodrug and the RGD peptidomimetic on the BL side, the methylester prodrugs 1b and 2b were approximately 12-fold more able to permeate than were the RGD peptidomimetics 1a and 2a. When similar analysis of the transport data for the coumarin prodrugs 3a and 3b was performed, they were shown to be approximately 6-fold and 5-fold more able to permeate than were the RGD peptidomimetics 1a and 12a, respectively.
CONCLUSION: The coumarin-based cyclic prodrugs 3a and 3b were chemically less stable, but metabolically more stable, then the methylester based linear prodrugs. The esterase stability of the cyclic prodrugs 3a and 3b means that they are transported intact across the Caco-2 cell monolayer in contrast to the methylester prodrugs 1b and 2b, which undergo facile bioconversion during their transport to the RGD peptidomimetics. However, both prodrug systems successfully delivered more (5-12-fold) of the RGD peptidomimetic and/or the precursor (prodrug) than did the RGD peptidomimetics themselves.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9706046     DOI: 10.1023/a:1011975404789

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  25 in total

1.  Serum esterases. I. Two types of esterase (A and B) hydrolysing p-nitrophenyl acetate, propionate and butyrate, and a method for their determination.

Authors:  W N ALDRIDGE
Journal:  Biochem J       Date:  1953-01       Impact factor: 3.857

2.  Caco-2 cell monolayers as a model for drug transport across the intestinal mucosa.

Authors:  A R Hilgers; R A Conradi; P S Burton
Journal:  Pharm Res       Date:  1990-09       Impact factor: 4.200

3.  Species and organ differences in first-pass metabolism of the ester prodrug L-751,164 in dogs and monkeys. In vivo and in vitro studies.

Authors:  T Prueksaritanont; L M Gorham; J D Ellis; C Fernandez-Metzler; P Deluna; J R Gehret; K L Strong; J H Hochman; B C Askew; M E Duggan; J D Gilbert; J H Lin; K P Vyas
Journal:  Drug Metab Dispos       Date:  1996-11       Impact factor: 3.922

4.  Discovery of an orally active non-peptide fibrinogen receptor antagonist.

Authors:  H U Stilz; B Jablonka; M Just; J Knolle; E F Paulus; G Zoller
Journal:  J Med Chem       Date:  1996-05-24       Impact factor: 7.446

5.  Disposition of L-738,167, a potent and long-acting fibrinogen receptor antagonist, in dogs. Dose-dependent pharmacokinetics.

Authors:  T Prueksaritanont; L M Gorham; J A Naue; T G Hamill; B C Askew; K P Vyas
Journal:  Drug Metab Dispos       Date:  1997-03       Impact factor: 3.922

6.  Orally active fibrinogen receptor antagonists. 2. Amidoximes as prodrugs of amidines.

Authors:  T Weller; L Alig; M Beresini; B Blackburn; S Bunting; P Hadváry; M H Müller; D Knopp; B Levet-Trafit; M T Lipari; N B Modi; M Müller; C J Refino; M Schmitt; P Schönholzer; S Weiss; B Steiner
Journal:  J Med Chem       Date:  1996-08-02       Impact factor: 7.446

7.  Non-peptide glycoprotein IIb/IIIa antagonists. 11. Design and in vivo evaluation of 3,4-dihydro-1 (1H)-isoquinolinone-based antagonists and ethyl ester prodrugs.

Authors:  J H Hutchinson; J J Cook; K M Brashear; M J Breslin; J D Glass; R J Gould; W Halczenko; M A Holahan; R J Lynch; G R Sitko; M T Stranieri; G D Hartman
Journal:  J Med Chem       Date:  1996-11-08       Impact factor: 7.446

8.  Esterase-sensitive cyclic prodrugs of peptides: evaluation of an acyloxyalkoxy promoiety in a model hexapeptide.

Authors:  G M Pauletti; S Gangwar; F W Okumu; T J Siahaan; V J Stella; R T Borchardt
Journal:  Pharm Res       Date:  1996-11       Impact factor: 4.200

9.  Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp-Phe sequence of fibrinogen. A proposal on the nature of the binding interaction between the Arg-guanidine of RGDX mimetics and the platelet GP IIb-IIIa receptor.

Authors:  J A Zablocki; M Miyano; R B Garland; D Pireh; L Schretzman; S N Rao; R J Lindmark; S G Panzer-Knodle; N S Nicholson; B B Taite
Journal:  J Med Chem       Date:  1993-06-25       Impact factor: 7.446

10.  Pharmacokinetics and pharmacodynamics of L-703,014, a potent fibrinogen receptor antagonist, after intravenous and oral administration in the dog.

Authors:  J S Barrett; R J Gould; J D Ellis; M M Holahan; M T Stranieri; J J Lynch; G D Hartman; N Ihle; M Duggan; O A Moreno
Journal:  Pharm Res       Date:  1994-03       Impact factor: 4.200

View more
  2 in total

Review 1.  Cyclization-activated prodrugs.

Authors:  Paula Gomes; Nuno Vale; Rui Moreira
Journal:  Molecules       Date:  2007-11-12       Impact factor: 4.411

2.  Angelica archengelica extract induced perturbation of rat skin and tight junctional protein (ZO-1) of HaCaT cells.

Authors:  N Kaushal; S Naz; Ak Tiwary
Journal:  Daru       Date:  2011       Impact factor: 3.117

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.